Kaposiform Lymphangiomatosis: A Patient Guide
At a Glance
Kaposiform lymphangiomatosis is a rare disease of abnormal lymphatic vessels that can affect the chest, lungs, and bones, causing breathing and bleeding problems. Treatment often combines specialist care with targeted medicines such as sirolimus or trametinib.
Kaposiform lymphangiomatosis (KLA) is a rare and complex condition that affects the lymphatic system, the network of vessels responsible for maintaining fluid balance and supporting the immune system. Unlike more common lymphatic marks, KLA is characterized by the presence of specialized spindle cells that cause the lymphatic vessels to grow and behave in an aggressive, disorganized manner. This condition is often described as a multisystem disease because it tends to involve several parts of the body simultaneously, particularly the chest cavity, lungs, and bones [1][2].
The behavior of KLA is largely driven by a specific genetic change known as an NRAS mutation. This is a somatic mutation, meaning it is a change that occurred in the affected tissue during development rather than being inherited from a parent in a way that passes down. This mutation acts like a permanent “on” switch, signaling the lymphatic cells to grow and spread abnormally. In the chest, this can lead to the buildup of fluid around the lungs and heart, which often impacts breathing. Additionally, KLA can interfere with how the blood clots—a process called consumptive coagulopathy—where the abnormal vessels “use up” the body’s platelets and clotting proteins, increasing the risk of bleeding [3][4].
Managing KLA has been transformed in recent years by the development of targeted therapies. Because researchers now understand the genetic pathways involved, doctors can use medications such as mTOR inhibitors (sirolimus) and MEK inhibitors (trametinib) to specifically block the signals driving the disease. These treatments aim to stabilize the lymphatic vessels, improve blood counts, and reduce fluid accumulation. Because the disease affects so many different systems, care is best managed by a multidisciplinary vascular anomalies team—a group of specialists including hematologists, radiologists, and pulmonologists who coordinate every aspect of treatment [5][6].
While KLA is a serious and life-altering diagnosis, the shift toward precision medicine means that care is more personalized, though responses still vary. Living with KLA requires ongoing vigilance and long-term monitoring, but the goal of modern treatment is to manage the disease effectively so that patients can focus on their daily lives. You are not alone in this journey; you are supported by a dedicated community of experts and families committed to navigating this complex condition together [7][8].
In this guide
6 chapters
Understanding Kaposiform Lymphangiomatosis
Learn what Kaposiform lymphangiomatosis is, how it affects the chest and blood clotting, NRAS testing, symptoms, and current treatments such as sirolimus.
Recognizing Symptoms and Emergency Signs
Learn which Kaposiform lymphangiomatosis symptoms need emergency care, including breathing trouble, bleeding, bruising, chest pain, and signs of low platelets.
The Biology of KLA and How It Differs from Other Conditions
Learn how Kaposiform lymphangiomatosis (KLA) differs biologically from GLA, Gorham-Stout disease, and KHE, including NRAS Q61R and spindle-cell patterns.
The Diagnostic Journey: Imaging, Biopsy, and Biomarkers
Learn how Kaposiform lymphangiomatosis is diagnosed with CT, MRI, biopsy, NRAS Q61R liquid biopsy, and Ang-2 testing, including biopsy risks and test limits.
Treating KLA: Specialist-Guided Options and Supportive Care
Learn how kaposiform lymphangiomatosis is treated with sirolimus, trametinib, drainage, embolization, transfusions, and specialist-guided supportive care.
Long-Term Monitoring and Life with KLA
Learn how Kaposiform lymphangiomatosis is monitored long term, including blood tests, imaging, medication safety, scan anxiety, and daily-life support.
Common questions in this guide
What is kaposiform lymphangiomatosis?
Is KLA caused by an inherited gene?
What problems can KLA cause?
What medicines are used to treat KLA?
What specialists care for someone with KLA?
When should someone with KLA seek urgent help?
Get notified when new evidence is published on Kaposiform lymphangiomatosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
Kaposiform Lymphangiomatosis: Pathologic Aspects in 43 Patients.
Perez-Atayde AR, Debelenko L, Al-Ibraheemi A, et al.
The American journal of surgical pathology 2022; (46(7)):963-976 doi:10.1097/PAS.0000000000001898.
PMID: 35385405 - 2
Potential biomarkers of kaposiform lymphangiomatosis.
Ozeki M, Nozawa A, Kawamoto N, et al.
Pediatric blood & cancer 2019; (66(9)):e27878 doi:10.1002/pbc.27878.
PMID: 31207041 - 3
A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.
Barclay SF, Inman KW, Luks VL, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(7)):1517-1524 doi:10.1038/s41436-018-0390-0.
PMID: 30542204 - 4
Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.
Ji Y, Chen S, Peng S, et al.
Orphanet journal of rare diseases 2019; (14(1)):165 doi:10.1186/s13023-019-1147-9.
PMID: 31277673 - 5
MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.
Alharbi S, Wagner A, Merkle S, et al.
Pediatric blood & cancer 2026; (73(3)):e70002 doi:10.1002/1545-5017.70002.
PMID: 41496696 - 6
Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.
Brown G, McNab S, Keogh S, et al.
Case reports in pediatrics 2026; (2026()):7037459 doi:10.1155/crpe/7037459.
PMID: 42639465 - 7
Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus.
Iacobas I, Adams DM, Pimpalwar S, et al.
Pediatric blood & cancer 2020; (67(1)):e28036 doi:10.1002/pbc.28036.
PMID: 31617676 - 8
Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment.
McDaniel CG, Adams DM, Steele KE, et al.
Pediatric blood & cancer 2023; (70(4)):e30219 doi:10.1002/pbc.30219.
PMID: 36683202
This page is for informational purposes only and does not constitute medical advice about kaposiform lymphangiomatosis. Your vascular anomalies team should guide decisions about symptoms, bleeding or breathing emergencies, and treatment for you or your child.